Related Experiment Video
Updated: Apr 13, 2026
Analysis of Pulmonary Dendritic Cell Maturation and Migration during Allergic Airway Inflammation
Published on: July 23, 2012
MicroRNA-155 modulates P2R signaling and Th2 priming of dendritic cells during allergic airway inflammation in mice
A Zech1, C K Ayata1, F Pankratz2
1Department of Pneumology, University Medical Centre, Freiburg, Germany.
Background:
Dendritic cells (DCs) are the professional antigen-presenting cells (APCs) in the lung. They are known to be key players in the induction and maintenance of allergic asthma by cross-linking innate and adaptive immune responses. MicroRNAs (miRNAs) are known to influence cell fate and function by translational suppression or induction of messenger RNA (mRNA) degradation. miR-155 has been shown to be a crucial regulator of the immune system. However, its function in the pathogenesis of allergic airway inflammation (AAI) is not completely elucidated yet.
Methods:
Wild type (WT) and miR-155-deficient (miR-155(-/-) ) mice were used in ovalbumin (OVA) and house dust mite (HDM) models of AAI. Adoptive transfer of sensitized DCs to the lungs, migration, and T-cell priming assays were used to investigate the functional relevance of miR-155 in DCs.
Results:
miR-155(-/-) mice showed reduced eosinophilic airway inflammation compared to WT mice in both models of AAI. Furthermore, miR-155(-/-) DCs showed limited Th2 priming capacity and failed to induce airway inflammation in allergen-exposed WT mice. miR-155 deficiency on DCs was also associated with impaired purinergic receptor signaling, as miR-155(-/-) DCs showed reduced chemotaxis and IL-1beta secretion upon stimulation with ATP, probably due to direct targeting of ectonucleoside triphosphate diphosphohydrolases (ENTPD) by miR-155.
Conclusions:
miR-155 deficiency alleviates AAI by diminishing Th2 priming capacity and ATP-/P2R-induced activation of DCs in mice, suggesting this miRNA as a potential therapeutic target of AAI.
Insights
MicroRNA-155 deficiency in dendritic cells reduces allergic airway inflammation by impairing T-cell responses and purinergic signaling, suggesting miR-155 as a therapeutic target for asthma.
Area of Science:
- Immunology
- Molecular Biology
- Respiratory Medicine
Background:
- Dendritic cells (DCs) are key antigen-presenting cells (APCs) in lung immunity, crucial for allergic asthma pathogenesis.
- MicroRNAs (miRNAs), like miR-155, regulate immune cell function, but miR-155's specific role in allergic airway inflammation (AAI) requires further elucidation.
Purpose of the Study:
- To investigate the functional role of miR-155 in dendritic cells during allergic airway inflammation (AAI).
- To determine if miR-155 deficiency impacts DC function and subsequent immune responses in asthma models.
Main Methods:
- Utilized wild type (WT) and miR-155-deficient (miR-155(-/-)) mice in ovalbumin (OVA) and house dust mite (HDM) induced AAI models.
- Employed adoptive transfer of DCs, migration assays, and T-cell priming assays to assess DC function.
- Analyzed purinergic receptor signaling, including chemotaxis and IL-1beta secretion upon ATP stimulation.
Main Results:
- miR-155(-/-) mice exhibited significantly reduced eosinophilic airway inflammation compared to WT mice.
- miR-155-deficient DCs demonstrated impaired Th2 cell priming capacity and failed to induce airway inflammation.
- miR-155 deficiency in DCs led to compromised purinergic receptor signaling, evidenced by reduced chemotaxis and IL-1beta secretion.
Conclusions:
- miR-155 deficiency alleviates AAI by reducing Th2 priming and DC activation via ATP/P2R signaling.
- These findings highlight miR-155 as a potential therapeutic target for allergic airway inflammation.
